Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > POC in humans has been acheived is that it

<< Previous

Bullboard Posts

Next >>

Comment by Saurus100on May 02, 2024 12:22pm

88 Views

Post# 36019740

RE:RE:RE:RE:POC in humans has been acheived is that it

Rusty, With all due respect, the press release's title and content say, "It will present long-term efficacy, safety, and pharmacokinetic (PK) data." Therefore, I expect new information regarding long-term efficacy, aren't you? I agree with all of you; we have been disappointed many times... But when you say the data they will present is not focused on efficacy, is that a feeling you have, or is it based on a conversation you had with management?

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec